Venetoclax as Part of Pre-Transplant Chemotherapy
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 324 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- BCL-2 Inhibitor, Chemotherapy
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1571
- NCT Identifier
- NCT04708054
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.